Reunion Neuroscience Inc. (TSE:REUN – Get Free Report) shares traded down 2.7% during mid-day trading on Monday . The company traded as low as C$1.41 and last traded at C$1.42. 339 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 12,447 shares. The stock had previously closed at C$1.46.
Reunion Neuroscience Stock Performance
The stock has a market capitalization of C$16.64 million, a P/E ratio of -0.43 and a beta of 4.20. The firm has a fifty day moving average of C$1.43.
About Reunion Neuroscience
Reunion Neuroscience Inc, a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Read More
- Five stocks we like better than Reunion Neuroscience
- Dividend Payout Ratio Calculator
- United Airlines Soars on Earnings Beat
- What Are Dividend Champions? How to Invest in the Champions
- J.B. Hunt Hits the Skids: Lower Prices to Come
- The “How” and “Why” of Investing in 5G Stocks
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
